Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H26N2O3 |
| Molecular Weight | 330.4213 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(NC(=C2)C(=O)N3CCC(CC(C)(C)O)CC3)C=C1
InChI
InChIKey=OXSCPDKUZWPWFR-UHFFFAOYSA-N
InChI=1S/C19H26N2O3/c1-19(2,23)12-13-6-8-21(9-7-13)18(22)17-11-14-10-15(24-3)4-5-16(14)20-17/h4-5,10-11,13,20,23H,6-9,12H2,1-3H3
| Molecular Formula | C19H26N2O3 |
| Molecular Weight | 330.4213 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
913 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
3148 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
7033 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
13651 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
6634 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
2277 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30745 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
98708 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
320369 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
539312 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
108693 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
41251 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
30 mg 1 times / day multiple, oral dose: 30 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
23.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
26.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
22.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24771350/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASP-9521 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 12:47:25 GMT 2025
by
admin
on
Wed Apr 02 12:47:25 GMT 2025
|
| Record UNII |
AA79G37CPR
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000042376
Created by
admin on Wed Apr 02 12:47:25 GMT 2025 , Edited by admin on Wed Apr 02 12:47:25 GMT 2025
|
PRIMARY | |||
|
25210792
Created by
admin on Wed Apr 02 12:47:25 GMT 2025 , Edited by admin on Wed Apr 02 12:47:25 GMT 2025
|
PRIMARY | |||
|
AA79G37CPR
Created by
admin on Wed Apr 02 12:47:25 GMT 2025 , Edited by admin on Wed Apr 02 12:47:25 GMT 2025
|
PRIMARY | |||
|
ASP-9521
Created by
admin on Wed Apr 02 12:47:25 GMT 2025 , Edited by admin on Wed Apr 02 12:47:25 GMT 2025
|
PRIMARY | MedKoo CAT NO: 205818; CAS NO: 1126084-37-4; Description: ASP9521 is a novel, selective, orally bioavailable inhibitor of 17.BETA.-hydroxysteroid dehydrogenase type 5 (17.BETA.HSD5AKR1C3). ASP9521 has demonstrated anti-tumour activity in in vitro and in vivo preclinical models. ASP9521 inhibited conversion of androstenedione (AD) into testosterone (T) by recombinant human or cynomolgus monkey AKR1C3 in a concentration-dependent manner (IC50,human: 11 nmol/L - IC50,monkey: 49 nmol/L). ASP9521 showed >100-fold selectivity for AKR1C3 over the isoform AKR1C2. In LNCaP-AKR1C3 cells, ASP9521 suppressed AD-dependent PSA production and cell proliferation. In patients with mCRPC, ASP9521 demonstrated dose-proportional increase in exposure over the doses evaluated, with an acceptable safety and tolerability profile. However, the novel androgen biosynthesis inhibitor showed no relevant evidence of clinical activity. (Last update: 11/18/2015). | ||
|
C133224
Created by
admin on Wed Apr 02 12:47:25 GMT 2025 , Edited by admin on Wed Apr 02 12:47:25 GMT 2025
|
PRIMARY | |||
|
1126084-37-4
Created by
admin on Wed Apr 02 12:47:25 GMT 2025 , Edited by admin on Wed Apr 02 12:47:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Results: ASP9521 showed potent inhibitory effect on enzymatic conversion from AD to T by both human AKR1C3 and cynomolgus monkey homologues in a concentration-dependent manner, with IC50 values of 11 and 49 nmol/L, respectively ASP9521 suppressed both AD-dependent PSA production and cell proliferation in LNCaP cells exogenously expressing AKR1C3 in vitro. The bioavailability of ASP9521after oral administration of 1mg/kg were 30% and 78% in rat and dog, respectively. Furthermore, ASP9521 single oral administration of 3 mg/kg suppressed AD-induced intratumoral T production in CWR22R xenografted castrate nude mice, and this inhibitory effect was maintained for 24 h. In addition, ASP9521 was rapidly eliminated from plasma after oral administration while its intratumoral concentration remained high in tumors expressing AKR1C3.
|
